Sign Out
Dolutegravir (as sodium)/Lamivudine/Tenofovir Disoproxil Fumarate 50mg/300mg/300mg Tablets is a fixed dose combination of Lamivudine, Tenofovir Disoproxil Fumarate and Dolutegravir.
It is indicated for the treatment of Human Immunodeficiency Virus (HIV) infected adults and adolescents above 12 years of age weighing at least 40 kg (see Precautions and Pharmacology: Pharmacodynamics under Actions).
The choice of Dolutegravir (as sodium)/Lamivudine/Tenofovir Disoproxil Fumarate 50mg/300mg/300mg Tablets to treat antiretroviral experienced patients with HIV-1 infection should be based on individual viral resistance testing and/or the treatment history of the patient. Consideration should be given to official treatment guidelines for HIV-1 infection (e.g. by WHO).
No data are available to support the combination of Dolutegravir (as sodium)/Lamivudine/Tenofovir Disoproxil Fumarate 50mg/300mg/300mg Tablets and other antiretroviral agents.
Continue with Google